Larimar Therapeutics shares surge 10.58% intraday on positive Nomlabofusp study data and FDA BLA submission updates for Friedreich’s Ataxia.

Larimar Therapeutics, Inc. (LRMR) surged 10.58% intraday following the announcement of positive data from its long-term open-label study of Nomlabofusp for Friedreich’s Ataxia, along with updates to the drug’s development program. The company also disclosed a conference call to discuss regulatory strategies for the therapy, signaling progress toward potential FDA approval. These developments, highlighting clinical advancements in a rare disease treatment, likely boosted investor confidence in the stock’s growth prospects.